Neogenomics Inc. [NEO] stock is trading at $15.16, up 2.71%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The NEO shares have gain 2.99% over the last week, with a monthly amount drifted -6.82%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 20, March 2024, NeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) Report. In a post published today on Yahoo Finance, NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today released its 2023 Environmental, Social, and Governance (ESG) Report highlighting progress toward building a more sustainable, diverse, and equitable company that delivers exceptional customer experience and advanced testing options. This inaugural report details the performance and management of NeoGenomics’ commitment to its core values of quality, integrity, accountability, teamwork, and innovation.
From an analyst’s perspective:
Neogenomics Inc. [NASDAQ: NEO] stock has seen the most recent analyst activity on December 29, 2023, when BTIG Research reiterated its Buy rating and also revised its price target to $21 from $25. Previously, Stephens upgraded its rating to Overweight on August 21, 2023, and kept the price target unchanged to $18. On May 16, 2023, downgrade downgraded it’s rating to Mkt Perform. BTIG Research upgraded its rating to a Buy but stick to its price target of $25 on May 09, 2023. The Benchmark Company upgraded its rating to a Buy but $20 remained the price target by the analyst firm on February 24, 2023. Needham upgraded its rating to Buy for this stock on February 01, 2023, but kept the price target unchanged to $15. In a note dated August 26, 2022, The Benchmark Company downgraded an Hold rating on this stock.
Neogenomics Inc. [NEO] stock has fluctuated between $11.03 and $21.22 over the past year. Currently, Wall Street analysts expect the stock to reach $22.86 within the next 12 months. Neogenomics Inc. [NASDAQ: NEO] shares were valued at $15.16 at the most recent close of the market. An investor can expect a potential return of 50.79% based on the average NEO price forecast.
Analyzing the NEO fundamentals
Neogenomics Inc. [NASDAQ:NEO] reported sales of 591.64M for the trailing twelve months, which represents a growth of 12.15%. Gross Profit Margin for this corporation currently stands at 0.41% with Operating Profit Margin at -0.17%, Pretax Profit Margin comes in at -0.16%, and Net Profit Margin reading is -0.15%. To continue investigating profitability, this company’s Return on Assets is posted at -0.05, Equity is -0.09 and Total Capital is -0.07. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.65.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.86 points at the first support level, and at 14.55 for the second support level. However, for the 1st resistance point, the stock is sitting at 15.38, and for the 2nd resistance point, it is at 15.59.
Neogenomics Inc. [NEO] reported earnings per share of $0.03 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.02/share, meaning a difference of $0.05 and a surprise factor of 250.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $0 per share as compared to estimates of -$0.07 per share, a difference of $0.07 representing a surprise of 100.00%.
Ratios To Look Out For
For context, Neogenomics Inc.’s Current Ratio is 6.20. Further, the Quick Ratio stands at 5.95, while the Cash Ratio is 3.56. Considering the valuation of this stock, the price to sales ratio is 3.27, the price to book ratio is 2.05.
Transactions by insiders
Recent insider trading involved TETRAULT LYNN A., Director, that happened on Mar 04 ’24 when 6112.0 shares were sold. General Counsel, Olivo Alicia C completed a deal on Feb 15 ’24 to sell 2587.0 shares. Meanwhile, General Counsel Olivo Alicia C sold 2669.0 shares on Nov 17 ’23.
